Protagenic Therapeutics, Inc. Enters into Amendment No. 1 to At Market Issuance Sales Agreement
On January 9, 2025, Protagenic Therapeutics, Inc. announced that it has entered into Amendment No. 1 to the At Market Issuance Sales Agreement with B. Riley Securities, Inc. The Sales Agreement, dated July 2, 2021, enables the company to offer and sell shares of its common stock through the Agent, with an aggregate offering price […]
More Stories
Traders Buy Large Volume of Invesco Solar ETF Call Options (NYSEARCA:TAN)
Invesco Solar ETF (NYSEARCA:TAN – Get Free Report) was the recipient of some unusual options trading on Monday. Stock investors...
Investors Buy High Volume of Vital Energy Call Options (NYSE:VTLE)
Vital Energy, Inc. (NYSE:VTLE – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired 7,208 call...
Stock Traders Purchase Large Volume of Call Options on Evolv Technologies (NASDAQ:EVLV)
Evolv Technologies Holdings, Inc. (NASDAQ:EVLV – Get Free Report) was the recipient of some unusual options trading activity on Tuesday....
Abeona Therapeutics Sees Unusually Large Options Volume (NASDAQ:ABEO)
Abeona Therapeutics Inc (NASDAQ:ABEO – Get Free Report) was the recipient of some unusual options trading on Monday. Stock investors...
Stock Traders Buy High Volume of Direxion Daily Semiconductors Bull 3x Shares Call Options (NYSEARCA:SOXL)
Direxion Daily Semiconductors Bull 3x Shares (NYSEARCA:SOXL – Get Free Report) was the recipient of some unusual options trading on...
NuScale Power (NYSE:SMR) Shares Gap Up on Better-Than-Expected Earnings
NuScale Power Co. (NYSE:SMR – Get Free Report)’s share price gapped up before the market opened on Tuesday following a...